Six year follow-up results of a phase II study of imatinib in late chronic phase (L-CP) chronic myeloid leukemia (CML) post interferon-a (IFN) Refractoriness/Intolerance.

被引：0
|
作者：
Kantarjian, Hagop M.
Sawyers, Charles
Hochhaus, Andreas
Schiffer, Charles A.
Guilhot, Francois
Niederwieser, Dietger W.
Gambacorti, Carlo
Stone, Richard M.
Fischer, Thomas
Goldman, John
Krahnke, T.
Mone, M.
Talpaz, Moshe
Druker, Brian J.
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Calif Los Angeles, Los Angeles, CA USA
[3] Univ Heidelberg, D-6800 Mannheim, Germany
[4] Karmanos Canc Inst, Detroit, MI USA
[5] CHU La Miletrie, Poitiers, France
[6] Univ Leipzig, D-7010 Leipzig, Germany
[7] Inst Natl Tumori, Milan, Italy
[8] Dana Farber Canc Inst, Boston, MA USA
[9] Univ Mainz, D-6500 Mainz, Germany
[10] NHLBI, Bethesda, MD 20892 USA
[11] Univ Michigan, Ann Arbor, MI 48109 USA
[12] Oregon Hlth Sci Univ, Portland, OR 97201 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
428
引用
收藏
页码：130A / 131A
页数：2
相关论文
共 50 条
  • [31] Significance of marrow fibrosis in chronic phase chronic myelogenous leukemia (CML) post interferon-a failure treated with imatinib mesylate therapy.
    Alvarez, RH
    Kantarjian, HM
    Bueso-Ramos, C
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Shan, JQ
    Cortes, J
    BLOOD, 2004, 104 (11) : 803A - 803A
  • [32] Imatinib (Glivec®) in patients with Ph plus chronic myeloid leukemia in chronic phase after interferon failure:: Results of a phase II trial of the Italian Cooperative Study Group on CML (ICSG on CML).
    Bassi, S
    Trabacchi, E
    Bonifazi, F
    Testoni, N
    Luatti, S
    Alberti, D
    De Vivo, A
    Pane, F
    Martinelli, G
    Amabile, M
    Saglio, G
    Cilloni, D
    Montefusco, E
    Tura, S
    Rosti, G
    Baccarani, M
    BLOOD, 2002, 100 (11) : 783A - 783A
  • [33] Primary results of the phase 4 BYOND study of bosutinib for pretreated chronic phase (CP) chronic myeloid leukemia (CML)
    Hochhaus, A.
    Gambacorti-Passerini, C.
    Saussele, S.
    Gjertsen, Tore B.
    Bruemmendorf, T. H.
    Abboud, C.
    le Coutre, P.
    Smith, B. D.
    Giraldo-Castellano, P.
    Stromberg, U.
    Bardy-Bouxin, N.
    Viqueira, A.
    Leip, E.
    Leone, J.
    Rosti, G.
    Watts, J.
    Giles, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 129 - 130
  • [34] Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML)
    Gambacorti-Passerini, Carlo
    Abboud, Camille
    Gjertsen, Bjorn Tore
    Bruemmendorf, Tim
    Smith, B. Douglas
    Giraldo-Castellano, Pilar
    Stromberg, Ulla
    Saussele, Susanne
    Bardy-Bouxin, Nathalie
    Viqueira, Andrea
    Leip, Eric
    Leone, Jocelyn
    Rosti, Gianantonio
    Watts, Justin
    Giles, Frank
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S290 - S290
  • [35] Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up
    Larson, R. A.
    Kim, D.
    Rosti, G.
    Stenke, L.
    Pasquini, R.
    Hoenekopp, A.
    Blakesley, R. E.
    Gallagher, N. J.
    Hochhaus, A.
    Hughes, T. P.
    Saglio, G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up
    Gambacorti-Passerini, C.
    Cortes, J. E.
    Kim, D.
    Kantarjian, H.
    Khattry, N.
    Lipton, J. H.
    Powell, C.
    Harris, P.
    Countouriotis, A. M.
    Brummendorf, T. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Dasatinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) In the DASISION Trial: 18-Month Follow-up
    Shah, Neil
    Kantarjian, Hagop
    Hochhaus, Andreas
    Cortes, Jorge E.
    Bradley-Garelik, M. Brigid
    Zhu, Chao
    Baccarani, Michele
    BLOOD, 2010, 116 (21) : 94 - 94
  • [38] A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP)
    Rosti, G.
    le Coutre, P.
    Bhalla, K.
    Giles, F.
    Ossenkoppele, G.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Baccarani, M.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Borthakur, Gautam
    Ravandi, Farhad
    Verstovsek, Srdan
    Daver, Naval G.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    Skinner, Jeff
    Konopleva, Marina
    Pierce, Sherry
    Jabbour, Elias
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [40] BUSULFAN, AND NOT DURATION OF DISEASE, RESULTS IN DECREASE OF RESPONSE TO IMATINIB IN VERY LATE CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA (CML)
    Zaritskey, A.
    Martinkevich, I.
    Shuvaev, V.
    Abdulkadyrova, A.
    Udalieva, V.
    Usacheva, E.
    Shikhbabava, D.
    Golubeva, M.
    Meresii, S.
    Machulaitene, E.
    Zotova, I.
    Poznyak, E.
    Koryagina, E.
    Ilina, N.
    Shneider, T.
    Romanova, E.
    Salamatova, E.
    Lazorko, N.
    Lomaia, E.
    Abdulkadyrov, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 544 - 544
12345